New BioAge Drug Prevents Death From COVID-19 in Old Mice by Reversing Immune Aging

A Phase 2 clinical trial is testing the new drug’s ability to reduce mortality in older people hospitalized with[{” attribute=””>COVID-19. By directly targeting immune aging, BGE-175 could effectively treat emerging COVID variants that evade vaccine-based immunity.

The immune system deteriorates with age, making COVID-19 particularly deadly in older people — but to date, no clinically available medication addresses this key risk factor. A study published today (March 21, 2022) in Nature shows that an oral drug that reverses multiple aspects of immune aging effectively prevents death in a mouse model of COVID-19, suggesting that the medication could be used to protect the elderly patients who are at greatest risk in the pandemic. 

In the study, daily doses of BGE-175 (asapiprant) protected aged mice from a lethal dose of (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = id; js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.6"; fjs.parentNode.insertBefore (js, fjs); } (document, 'script', 'facebook-jssdk'));

Leave a Reply

Your email address will not be published.